tak 779 has been researched along with vicriviroc in 7 studies
| Studies (tak 779) | Trials (tak 779) | Recent Studies (post-2010) (tak 779) | Studies (vicriviroc) | Trials (vicriviroc) | Recent Studies (post-2010) (vicriviroc) |
|---|---|---|---|---|---|
| 118 | 1 | 35 | 101 | 20 | 36 |
| Protein | Taxonomy | tak 779 (IC50) | vicriviroc (IC50) |
|---|---|---|---|
| C-C chemokine receptor type 5 | Homo sapiens (human) | 0.0016 | |
| C-C chemokine receptor type 5 | Mus musculus (house mouse) | 0.0009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, D; Hisaichi, K; Jenkinson, S; Kazmierski, WM; Maeda, K; Matsunaga, N; Minamoto, C; Mitsuya, H; Nakai, H; Nishiyama, T; Nishizawa, R; Sagawa, K; Shibayama, S; Tada, H; Takaoka, Y | 1 |
| Fukushima, D; Hisaichi, K; Maeda, K; Minamoto, C; Mitsuya, H; Murota, M; Nakai, H; Nishiyama, T; Nishizawa, R; Sagawa, K; Shibayama, S; Tada, H; Takaoka, Y | 1 |
| Horuk, R; Pease, J | 1 |
| Dioszegi, M; Ji, C; Kondru, R; Mirzadegan, T; Rotstein, D; Sankuratri, S; Zhang, J | 1 |
| Arenzana-Seisdedos, F | 1 |
| Henrich, TJ; Konstantinidis, I; Kuritzkes, DR; Leopold, KE; Lewine, NR; Sagar, M; Tsibris, AM | 1 |
| Coakley, E; Greaves, W; Gulick, RM; Henrich, TJ; Hu, Z; Kuritzkes, DR; Lee, SH; Putcharoen, O; Tsibris, AM; Vanichanan, J | 1 |
1 review(s) available for tak 779 and vicriviroc
| Article | Year |
|---|---|
[Viral entry as therapeutic target. Current situation of entry inhibitors].
Topics: Adult; Amides; Benzoates; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Chemokines, CXC; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Models, Molecular; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Spiro Compounds; Structure-Activity Relationship; Triazoles; Virus Attachment; Virus Internalization | 2008 |
1 trial(s) available for tak 779 and vicriviroc
| Article | Year |
|---|---|
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Kinetics; Molecular Sequence Data; Mutation; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Virus Internalization | 2012 |
5 other study(ies) available for tak 779 and vicriviroc
| Article | Year |
|---|---|
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Topics: Administration, Oral; Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line, Tumor; Diketopiperazines; Drug Evaluation, Preclinical; HIV Core Protein p24; HIV-1; Humans; Microsomes, Liver; Rats; Receptors, CCR5; Spiro Compounds; Stereoisomerism | 2011 |
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Diketopiperazines; Dogs; Drug Evaluation, Preclinical; Guinea Pigs; Haplorhini; Humans; Rabbits; Rats; Receptors, CCR5; Structure-Activity Relationship | 2011 |
Chemokine receptor antagonists.
Topics: Animals; Autoimmune Diseases; Humans; Receptors, Chemokine | 2012 |
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Topics: Amides; Amino Acid Sequence; Animals; Anti-HIV Agents; Benzoates; Binding Sites; CCR5 Receptor Antagonists; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Maraviroc; Membrane Fusion; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutagenesis, Site-Directed; Piperazines; Piperidines; Protein Structure, Secondary; Protein Structure, Tertiary; Pyrimidines; Quaternary Ammonium Compounds; Radioligand Assay; Receptors, CCR5; Sequence Homology, Amino Acid; Spiro Compounds; Static Electricity; Transfection; Triazoles | 2008 |
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Topics: Amides; Amino Acid Sequence; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Evolution, Molecular; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Peptide Fragments; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Triazoles | 2010 |